Brief: Orchard Therapeutics Reports Third Quarter Results
06/11/2019 23:18
Nov 6 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL
RESULTS AND ACHIEVEMENT OF KEY 2019 MILESTONES FOR
NEUROMETABOLIC AND PRIMARY IMMUNE DEFICIENCIES FRANCHISES
* QTRLY LOSS PER SHARE $0.38
* CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF SEPTEMBER 30,
2019,
WERE $366.2 MILLION
* Q3 EARNINGS PER SHARE VIEW $-0.43 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX1cpgJj
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln